secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001567264-24-000053
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics Q3 net loss $3.5M; first patient dosed in Phase 2 TNBC study
--------------------------------------------------------------------------------

- Net loss of $3.5M for Q3 2024 vs $2.3M a year ago; R&D expenses rose to $2.2M.
- Cash and equivalents $2.8M as of Sept 30, 2024; expected to fund operations into Q1 2025.
- First patient dosed in Phase 2 INVINCIBLE-4 study of INT230-6 in presurgical triple-negative breast cancer.
- Phase 3 INVINCIBLE-3 sarcoma study received regulatory authorizations in 8 countries; enrollment target 333 patients.
- Regulatory approvals obtained from Health Canada, EMA, Swissmedic, and Australia's TGA during Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000053/0001567264-24-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000053/intensity-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001567264-24-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer